Form 4: Immuneering CAO Acquires Shares via ESPP

Immuneering Corp's Chief Accounting Officer, Mallory Morales, acquired 14,497 shares of Class A Common Stock through the company's Employee Stock Purchase Plan.

Summary

• Mallory Morales, Chief Accounting Officer of Immuneering Corp (IMRX), acquired 14,497 shares of Class A Common Stock.
• The acquisition occurred on September 15, 2025, at a price of $1.428 per share.
• This transaction was made pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (ESPP) for the purchase period from March 16, 2025, through September 15, 2025.
• Following this transaction, Morales directly beneficially owns 27,233 shares of Class A Common Stock.
• The transaction is exempt under Rule 16b-3(c) of the Securities Exchange Act of 1934.

Sentiment

Score: 7

Explanation: The acquisition of shares by a Chief Accounting Officer through an ESPP is generally a positive indicator, demonstrating management's confidence and aligning their interests with shareholders.

Positives

• Chief Accounting Officer Mallory Morales increased her direct beneficial ownership in Immuneering Corp by acquiring 14,497 shares.
• The acquisition was made through the company's Employee Stock Purchase Plan (ESPP), indicating management's participation and confidence in the company.
• The purchase price of $1.428 per share reflects a discount (at least 15%) to the fair market value, a benefit for participating employees.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP").
• The shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value of a share of Class A Common Stock on the Enrollment Date of the relevant Offering Period.

Industry Context

Insider purchases, especially through employee plans like ESPPs, are generally viewed as a positive signal, indicating management's belief in the company's future prospects and alignment of interests with shareholders. This is a common practice in publicly traded companies to incentivize employees.

Comparison to Industry Standards

• Employee Stock Purchase Plans (ESPPs) are a standard compensation and retention tool across various industries, including biotechnology.
• The typical discount offered (e.g., at least 15% as implied here) is common for such plans, encouraging broad employee participation and aligning employee interests with shareholder value.
• No specific comparable companies or projects are mentioned in the filing to allow for a direct comparison of results.

Related Party Transactions

• The acquisition of shares by an officer through the company's Employee Stock Purchase Plan (ESPP) is a standard related party transaction, disclosed as part of a pre-approved program.

Stakeholder Impact

• Shareholders: Positive signal of insider confidence and alignment of interests.
• Employees: Demonstrates the benefit and participation in the company's ESPP.

Key Dates

Recommendation

This Form 4 filing reports a routine insider acquisition of shares through an Employee Stock Purchase Plan. While insider buying is generally a positive signal, this specific transaction, given its nature (ESPP) and the relatively small amount in the context of the company's overall market capitalization, is unlikely to be a significant catalyst for a strong buy or sell recommendation. It reinforces a "hold" stance, indicating continued confidence from management without suggesting an immediate, dramatic shift in the company's prospects.

Keywords

Immuneering Corp, IMRX, Mallory Morales, Chief Accounting Officer, insider transaction, Form 4, stock acquisition, ESPP, employee stock purchase plan, Class A Common Stock, beneficial ownership